On Monday, pizzaria chain Sbarro — an iconic name within the food court community at many of the nation’s malls — filed for Chapter 11 bankruptcy protection … again.
Top 5 Sliver Companies To Own In Right Now: InterMune Inc.(ITMN)
InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company?s research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Advisors' Opinion:- [By Ben Levisohn]
Intercept Pharmaceutical has surged 576% this year after gaining today, besting InterMune’s (ITMN) 119% spike and Sangamo BioSciences’ (SGMO) 63% advance.
- [By Ben Levisohn]
Shares of InterMune (ITMN) have jumped 36% to $73.40�after�Roche�(RHHBY) said it would buy the drug maker for $8.3 billion.
Burger King Worldwide�(BKW) has climbed 7.9% to $29.25�on reports that the hamburger joint is considering the purchase of Canadian coffee-outlet Tim Hortons�(THI) for the tax benefits. Tim Hortons has gained 15% to $72.00.
- [By Roberto Pedone]
InterMune (ITMN), a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. This stock closed up 13.4% at $38.92 in Monday's trading session.
Monday's Volume: 11.92 million
Three-Month Average Volume: 3.56 million
Volume % Change: 350%From a technical perspective, ITMN gapped sharply higher here right above its 50-day moving average of $32.38 with heavy upside volume. This monster spike higher on Monday pushed shares of ITMN into breakout and 52-week-high territory, since the stock took out some near-term overhead resistance levels at $36.71 to its former 52-week high of $38.73. Market players should now look for a continuation move to the upside in the short-term if ITMN manages to clear Monday's intraday high of $39.90 with strong volume.
Traders should now look for long-biased trades in ITMN as long as it's trending above $37 or above Monday's low of $35.85 and then once it sustains a move or close above $39.90 with volume that this near or above 3.56 million shares. If that move starts soon, then ITMN will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $45 to $50.
Top 5 Biotech Stocks To Own For 2014: Gentium SpA(GENT)
Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. It develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also offers sulglicotide that is developed from swine duodenum, and has ulcer healing and gastrointestinal protective properties in South Korea; and urokinase, which is made from human urine to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.
Advisors' Opinion:- [By Sean Williams]
A parabolic problem
It has also been a year to remember for shareholders of biopharmaceutical company Gentium (NASDAQ: GENT ) whose share price has catapulted approximately 600% off its lows thanks to growth in its lead drug Defibrotide (known as Defitelio in the European Union). - [By James Oberweis]
Gentium Spa (GENT) is focused on the development and commercialization of its leading product, defibrotide, to treat certain complications arising from chemotherapy, and bone marrow and stem cell transplantation therapy.
Top 5 Biotech Stocks To Own For 2014: ARIAD Pharmaceuticals Inc.(ARIA)
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By George Budwell]
Ariad Pharmaceuticals (NASDAQ: ARIA ) is an oncology company whose leukemia drug Iclusig made headlines recently when it was pulled from the market by the Food and Drug Administration after a late-stage trial showed an elevated risk of blood clots. Shares of Ariad fell more than 25% this week as a result, despite already being down more than 80% in the last month. The problem facing Ariad is clear: Iclusig is its bread and butter. So if the FDA does not allow it back on the market, and that looks doubtful at this point, Ariad is in big trouble. Currently, the company only has one other clinical candidate, and that drug is still in the very early stages of development.
Top 5 Biotech Stocks To Own For 2014: Incyte Corporation(INCY)
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Advisors' Opinion:- [By Ben Levisohn]
Vertex has dropped 6.1% to $66.97 today at 2:24 p.m. but it’s fall doesn’t seem to be having an impact on other biotech companies. Incyte (INCY) gained 2% to $39.77, Acorda Therapeutics (ACOR) has gained 0.7% to $30.83 and Regeneron Pharmaceuticals (REGN) has dropped 0.6% to $285.96.
- [By Paul Ausick]
Big earnings winners: Incyte Corp. (NASDAQ: INCY) up 34.4% to $36.02 on a successful drug trial, Target Corp. (NYSE: TGT) down 3.5% to $65.54 on weak earnings and lowered outlook, and Lowe�� Companies Inc. (NYSE: LOW ) up 4.4% at $46.01 on strong earnings and an improved outlook.
- [By Maxx Chatsko]
Pfizer will turn its immediate focus to Xeljanz, a novel JAK3 inhibitor, as it awaits phase 3 data from ertugliflozin several years from now. The drug class has swept the pharmaceutical industry by storm. Novartis (NYSE: NVS ) and Eli Lilly are developing JAK1 and JAK2 inhibitors for several applications with Incyte (NASDAQ: INCY ) , while a handful of other companies have molecules of their own. While companies have high hopes for the cancer-fighting potential of JAK inhibitors, such as Jakafi from Novartis and Incyte, the biggest opportunities may lie in the immunology market.
- [By Jim Jubak]
But a bigger reason to sell, in my opinion, right now, is a change in the risk/reward profile of the market as a whole. The recent sell off in momentum stocks��hich now looks like it's spreading to consumer discretionary leaders��akes me want to raise cash for the inevitable bounce back in these stocks. I don't know when we might see that bounce��nd I'm not buying yet, since I think we're still in ��atch a falling knife��territory. But when stocks such as FireEye (FEYE), or Palo Alto Networks (PANW), or Incyte (INCY), or Chipotle Mexican Grill (CMG) do bounce, the gains will be bigger and quicker than those in holding Citigroup.
No comments:
Post a Comment